Batu Chooses Unusual Path, Unusual Weapon

Crowdfunding Part of Financial Strategy; Cancer Fight Aims to Cut Tumors’ Blood Supply

When it comes to small and scrappy biotechs, Batu Biologics might take the cake. Led by a 25-year-old college dropout, Batu got its start with a $100,000 infusion of cash from a crowdfunding campaign the team launched online… the company has filed 29 patents, raised over $2 million, and is gearing up to start testing its anti-cancer vaccine in humans.

Download full article here

Continue →
0

Batu Publishes Oncotarget Paper

Batu Biologics Publishes Mechanistic Preclinical Data for ValloVax

Company authors peer reviewed publication describing the mechanism of action of the ValloVax™ mediated immune response

Batu Biologics, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced today the publication of mechanistic data for the ValloVax platform in the current issue of Oncotarget.

Read the full article at businesswire.com

Continue →
0

Batu announces formation of Clinical Advisory Board

Batu Biologics Welcomes Three Visionary Leaders to Its Newly Formed Clinical Advisory Board

CAB to oversee the clinical development of Batu Biologics’ tumor vasculature targeting immunotherapeutic, ValloVax™

Batu Biologics, a San Diego based immuno-oncology company focused on the development of its tumor angiogenesis targeting immune therapy, ValloVax™, announced today the formation of a Clinical Advisory Board to guide the company in the development of its lead program.

Read the full article at businesswire.com

Continue →
0

Batu Biologics Recruits Dr. Vijay Mahant to SAB

Batu Biologics Recruits Diagnostics Expert to Oversee Precision-Medicine Company Arm

Vijay Mahant, PhD, will lead efforts in the development of gene-guided precision medicine related to the ValloVax immune therapy

Batu Biologics, an immuno-oncology company dedicated to the development of its tumor-angiogenesis targeting immune therapy, ValloVax™, announced today the appointment of Vijay Mahant, PhD, to its Scientific Advisory Board.

Read the full article at businesswire.com

Continue →
0

Batu Biologics selected to present at Cavendish Global Forum

Forum uniquely brings together leading family offices, their foundations and sovereign wealth fund representatives seeking impact investment, grant-giving, and philanthropy opportunities within health and life sciences

Batu Biologics, an immuno-oncology company, announced today it has been selected to present at the Cavendish Global Health Impact Forum taking place February 15th to February 18th at the Breakers in Palm Beach, Florida.

Read the full article at businesswire.com

Continue →
0

Dr. Thomas Ichim joins as full-time CSO

Founder of Batu Biologics Expands Involvement as Chief Scientific Officer

Thomas Ichim, PhD, will oversee the scientific development of the ValloVax therapeutic program

Batu Biologics, an immuno-oncology company dedicated to the development of its tumor-angiogenesis targeting immune therapy, ValloVax™, announced today the appointment of Thomas Ichim, PhD, to the position of Chief Scientific Officer.

Read the full article at businesswire.com

Continue →
0

Vice Chair of Immunology at TSRI joins SAB

Vice Chairman of Immunology at The Scripps Research Institute to Assist with ValloVax™ Clinical Development

Argyrios Theofilopoulos, MD, Joins Batu’s Scientific Advisory Board

Batu Biologics, an immuno-oncology company dedicated to the development of its tumor-angiogenesis targeting immune therapy, ValloVax™, announced today the appointment of Argyrios Theofilopoulos, MD of The Scripps Research Institute to its scientific advisory board.

Read the full article at businesswire.com

Continue →
0
Page 1 of 5 12345